Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit.
BACKGROUND
Intrahepatic cholangiocarcinoma is rare, but its incidence is rapidly increasing in developed countries. Early detection and surgical extirpation offer the only hope for cure. Given the rarity of intrahepatic cholangiocarcinoma, there is limited knowledge regarding its natural history, clinicopathological characteristics, or outcomes following surgery. The primary aim of the current study is to report overall survival and recurrence-free survival outcomes following resection of intrahepatic cholangiocarcinoma. The secondary aim is to evaluate the impact of prognostic variables on outcomes.


METHODS
Between November 1990 and November 2009, 88 patients were evaluated for their suitability for potentially curative surgery; of these, 40 patients underwent potentially curative surgery. These patients are the principal subjects of the current analysis. Patients were assessed at monthly intervals for the first 3 months and then at six monthly intervals after treatment. Recurrence-free survival and overall survival were determined; 17 clinicopathological and treatment-related factors associated with recurrence-free survival and overall survival were evaluated through univariate and multivariate analyses.


RESULTS
No patient was lost to follow-up. The median follow-up was 31 months (range = 0-142 months). The median recurrence-free survival and overall survival after resection were 21 and 33 months, respectively. The 5-year survival rate was 28%. Four factors were associated with overall survival: carbohydrate antigen 19.9 (p = 0.020), clinical stage (p = 0.018), histological grade (p = 0.020), and lymph node metastases (p = 0.003). Two factors were associated with recurrence-free survival: carbohydrate antigen 19.9 (p = 0.002) and margin status (p = 0.002).


CONCLUSIONS
Hepatic resection is an efficacious treatment for intrahepatic cholangiocarcinoma. Clincopathological factors can predict outcome and should be used in the preoperative assessment of operability.
Saxena
Akshat
A
Hepatobiliary and Surgical Oncology Unit, UNSW Department of Surgery, St George Hospital, Kogarah, NSW 2217, Sydney, Australia.
Chua
Terence C
TC
Sarkar
Anik
A
Chu
Francis
F
Morris
David L
DL
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D001315:Australia / Q000453:epidemiology; D001650:Bile Duct Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000401:mortality* / Q000473:pathology / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D015996:Survival Rate
D015295:Antigens, Tumor-Associated, Carbohydrate
Oncology. 2004;66(3):167-79
15218306
Br J Surg. 2009 Aug;96(8):919-25
19591163
Ann Surg Oncol. 2009 Nov;16(11):3048-56
19626372
Surg Oncol Clin N Am. 1996 Apr;5(2):337-52
9019355
Ann Surg. 2008 Oct;248(4):626-37
18936576
Cancer. 2008 Oct 1;113(7):1614-22
18704990
Ann Surg Oncol. 2009 Feb;16(2):404-12
19037702
J Hepatobiliary Pancreat Surg. 2008;15(4):417-22
18670844
Radiother Oncol. 2010 Jan;94(1):47-52
19963295
World J Gastroenterol. 2009 Dec 21;15(47):5976-82
20014463
Surgery. 2008 Mar;143(3):366-74
18291258
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1198-203
16775181
Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7
19652971
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1495-501
18472359
Cancer. 1998 Nov 1;83(9):1923-9
9806650
J Cancer Res Clin Oncol. 2009 Aug;135(8):1073-80
19294418
World J Surg. 2008 Dec;32(12):2675-80
18843437
Ann Surg. 2005 Jan;241(1):134-43
15622001
J Am Coll Surg. 2009 Feb;208(2):218-28
19228533
Ann Surg Oncol. 2010 Feb;17(2):484-91
19876691
Semin Liver Dis. 2004 May;24(2):115-25
15192785
Am J Surg. 2011 Feb;201(2):203-8
19427630